Researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), and Tianjin Medical University General Hospital have developed a bioinspired lipid nanoparticle (LNP) that can deliver gene-editing machinery to the liver and reduce low-density lipoprotein (LDL) cholesterol, commonly known as "bad" cholesterol. The nanoparticles reduced LDL and total cholesterol by more than 20% after two doses, while showing fewer signs of inflammation and toxicity than comparator formulations. The findings were published in the Journal of Controlled Release.